Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 6/20 | 0.62 |
| ▸ | CTSK | P43235 | 5/20 | 0.62 |
| ▸ | CTSB | P07858 | 3/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
| ▸ | APP | P05067 | 4/20 | 0.45 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4860365 | 1.00 | CTSS (0.62) | CTSSCTSKCTSBATMCTSL | |
| SCHEMBL30597876 | 1.00 | CTSS (0.62) | CTSSCTSKCTSBATMCTSL | |
| SCHEMBL4598553 | 0.89 | CTSS (0.58) | CTSSCTSKCTSBATMCTSL | |
| SCHEMBL4859984 | 0.88 | CTSS (0.61) | CTSSCTSKCTSBATMCTSL | |
| SCHEMBL4859989 | 0.88 | CTSS (0.61) | CTSSCTSKCTSBATMCTSL | |
| SCHEMBL31758020 | 0.87 | ATM (0.55) | CTSSCTSKCTSBATMCTSL | |
| SCHEMBL489490 | 0.86 | ATM (0.70) | CTSSCTSKCTSBATMCTSL | |
| SCHEMBL489489 | 0.86 | ATM (0.70) | CTSSCTSKCTSBATMCTSL | |
| SCHEMBL1519945 | 0.86 | ATM (0.70) | CTSSCTSKCTSBATMCTSL | |
| SCHEMBL742226 | 0.86 | CTSL (0.62) | CTSSCTSKCTSBATMCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117486762-A | Novel compound and use method and application thereof | 中国医学科学院医药生物技术研究所 | 2024-02-02 | — | — | CN | disclosed |
| CN-116693414-A | Compound with 3CL protease inhibition activity and application thereof | 深圳市小分子新药创新中心有限公司 | 2023-09-05 | — | — | CN | disclosed |
| US-20080306040-A1 | Antibacterial amide macrocycles VII | AICURIS GMBH & CO. KG (DE) | 2008-12-11 | — | — | US | disclosed |
| US-20080306040-A1 | Antibacterial amide macrocycles VII | AICURIS GMBH & CO. KG (DE) | 2008-12-11 | — | — | US | disclosed |
| US-20080306040-A1 | Antibacterial amide macrocycles VII | AICURIS GMBH & CO. KG (DE) | 2008-12-11 | — | — | US | disclosed |
| WO-2007006548-A2 | ANTIBACTERIAL AMIDE MACROCYCLES VII | AICURIS GMBH & CO. KG (DE) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306040-A1 | Antibacterial amide macrocycles VII | AADAC, AAAS, NOD2 | CTSS 88/4885CTSK 93/4885CTSB 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.